WO2000067788A3 - Use of soluble costimulatory molecules to enhance immune responses - Google Patents

Use of soluble costimulatory molecules to enhance immune responses Download PDF

Info

Publication number
WO2000067788A3
WO2000067788A3 PCT/US2000/012435 US0012435W WO0067788A3 WO 2000067788 A3 WO2000067788 A3 WO 2000067788A3 US 0012435 W US0012435 W US 0012435W WO 0067788 A3 WO0067788 A3 WO 0067788A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune responses
costimulatory molecules
enhance immune
soluble costimulatory
molecules
Prior art date
Application number
PCT/US2000/012435
Other languages
French (fr)
Other versions
WO2000067788A2 (en
Inventor
Knut Sturmhoefel
Stanley F Wolf
Margot O'toole
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0010711-5A priority Critical patent/BR0010711A/en
Priority to IL14610600A priority patent/IL146106A0/en
Priority to JP2000616813A priority patent/JP2002544170A/en
Priority to CA002373256A priority patent/CA2373256A1/en
Priority to KR1020017014170A priority patent/KR20020001865A/en
Priority to AU48257/00A priority patent/AU4825700A/en
Application filed by Genetics Inst filed Critical Genetics Inst
Priority to EP00930437A priority patent/EP1181053A2/en
Priority to PL36091500A priority patent/PL360915A1/en
Publication of WO2000067788A2 publication Critical patent/WO2000067788A2/en
Publication of WO2000067788A3 publication Critical patent/WO2000067788A3/en
Priority to NO20015396A priority patent/NO20015396L/en
Priority to HK02102335.8A priority patent/HK1041810A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Methods of enhancing immune responses in which soluble forms of costimulatory molecules, e.g., B7 molecules, are administered to augment immune responses to antigens, e.g., to tumor cells and infectious agents are provided. The subject methods are useful for both prophylactic and therapeutic immunization of subjects.
PCT/US2000/012435 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses WO2000067788A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IL14610600A IL146106A0 (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses
JP2000616813A JP2002544170A (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune response
CA002373256A CA2373256A1 (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses
KR1020017014170A KR20020001865A (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses
AU48257/00A AU4825700A (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses
BR0010711-5A BR0010711A (en) 1999-05-06 2000-05-05 Use of soluble co-stimulatory molecules to enhance immune responses
EP00930437A EP1181053A2 (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses
PL36091500A PL360915A1 (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses
NO20015396A NO20015396L (en) 1999-05-06 2001-11-05 Use of soluble costimulatory molecules to enhance immune responses
HK02102335.8A HK1041810A1 (en) 1999-05-06 2002-03-26 Use of soluble costimulatory molecules to enhance immune responses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13294499P 1999-05-06 1999-05-06
US60/132,944 1999-05-06

Publications (2)

Publication Number Publication Date
WO2000067788A2 WO2000067788A2 (en) 2000-11-16
WO2000067788A3 true WO2000067788A3 (en) 2001-04-05

Family

ID=22456295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012435 WO2000067788A2 (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses

Country Status (15)

Country Link
EP (1) EP1181053A2 (en)
JP (1) JP2002544170A (en)
KR (1) KR20020001865A (en)
CN (1) CN1377279A (en)
AU (1) AU4825700A (en)
BR (1) BR0010711A (en)
CA (1) CA2373256A1 (en)
CZ (1) CZ20013964A3 (en)
HK (1) HK1041810A1 (en)
HU (1) HUP0201222A3 (en)
IL (1) IL146106A0 (en)
NO (1) NO20015396L (en)
PL (1) PL360915A1 (en)
WO (1) WO2000067788A2 (en)
ZA (1) ZA200109376B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (en) 1997-02-27 2004-04-19 日本たばこ産業株式会社 Cell surface molecules that mediate cell-cell adhesion and signal transduction
JP3871503B2 (en) 1999-08-30 2007-01-24 日本たばこ産業株式会社 Immune disease treatment
JP4210454B2 (en) 2001-03-27 2009-01-21 日本たばこ産業株式会社 Inflammatory bowel disease treatment
JP3597140B2 (en) 2000-05-18 2004-12-02 日本たばこ産業株式会社 Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
JP4212278B2 (en) 2001-03-01 2009-01-21 日本たばこ産業株式会社 Graft rejection inhibitor
WO2007005583A1 (en) * 2005-06-30 2007-01-11 Eisai Co., Ltd. Compounds for preparing immunological adjuvant
AU2006321890A1 (en) 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Methods and compositions for expanding T regulatory cells
WO2007067681A2 (en) 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Immunostimulatory compositions and methods
US9511151B2 (en) * 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CA2843274A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US20150056232A1 (en) * 2012-04-02 2015-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP3539564A1 (en) 2013-11-04 2019-09-18 UTI Limited Partnership Methods and compositions for sustained immunotherapy
KR20180011135A (en) 2015-05-06 2018-01-31 유티아이 리미티드 파트너쉽 Nanoparticle composition for continuous therapy
CN110743006B (en) * 2019-11-22 2020-08-25 北京启辰生生物科技有限公司 Composition for synergistically relieving immune cell failure and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006605A2 (en) * 1998-07-28 2000-02-10 Micromet Ag Heterominibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006605A2 (en) * 1998-07-28 2000-02-10 Micromet Ag Heterominibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN AOSHUANG ET AL: "Non-glycosylated human B7-1(CD80) retains the capacity to bind its counter-receptors.", FEBS LETTERS, vol. 428, no. 3, 29 May 1998 (1998-05-29), pages 127 - 134, XP002154489, ISSN: 0014-5793 *
MORO MONICA ET AL: "Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.", CANCER RESEARCH, vol. 59, no. 11, 1 June 1999 (1999-06-01), pages 2650 - 2656, XP002154490, ISSN: 0008-5472 *
RAO JAY B ET AL: "IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: Enhancement by simultaneous B7-1 expression.", JOURNAL OF IMMUNOLOGY, vol. 156, no. 9, 1996, pages 3357 - 3365, XP002154488, ISSN: 0022-1767 *
RENNERT PAUL ET AL: "The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion.", INTERNATIONAL IMMUNOLOGY, vol. 9, no. 6, 1997, pages 805 - 813, XP000971089, ISSN: 0953-8178 *

Also Published As

Publication number Publication date
IL146106A0 (en) 2002-07-25
JP2002544170A (en) 2002-12-24
WO2000067788A2 (en) 2000-11-16
KR20020001865A (en) 2002-01-09
HUP0201222A3 (en) 2004-07-28
CN1377279A (en) 2002-10-30
PL360915A1 (en) 2004-09-20
CA2373256A1 (en) 2000-11-16
EP1181053A2 (en) 2002-02-27
HK1041810A1 (en) 2002-07-26
CZ20013964A3 (en) 2002-06-12
AU4825700A (en) 2000-11-21
ZA200109376B (en) 2003-03-13
BR0010711A (en) 2002-02-13
NO20015396D0 (en) 2001-11-05
NO20015396L (en) 2002-01-02
HUP0201222A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
WO2000067788A3 (en) Use of soluble costimulatory molecules to enhance immune responses
WO1999033868A3 (en) Human papillomavirus vaccine
WO1999010375A3 (en) Vaccine against hpv
MXPA02005639A (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions.
WO2002102299A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
WO2002034205A3 (en) Using heat shock proteins to increase immune response
WO2001060402A3 (en) Proteosome influenza vaccine
NZ503830A (en) Papilloma virus capsomere vaccine formulations and methods of use
WO2005037190A3 (en) Multiplex vaccines
AU4322996A (en) Variants of human papilloma virus antigens
WO2001026681A3 (en) Method of obtaining cellular immune responses from proteins
HUP0402067A2 (en) Vaccines
AU2002347404A1 (en) In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2005002621A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
IL145982A0 (en) Vaccines
HUP0401753A3 (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
WO1999050303A3 (en) Immune response modulator alpha-2 macroglobulin complex
EP1115418A4 (en) Aglyco products and methods of use
WO2001079259A8 (en) Javelinization of protein antigens to heat shock proteins
CA2232344A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
WO2005025497A3 (en) Hpv cd8+ t-cell epitopes
WO2002054073A3 (en) Latent human tuberculosis model, diagnostic antigens, and methods of use
WO2002076485A3 (en) Vaccine for modulating between t1 and t2 immune responses
WO2000061766A3 (en) Telomerase-specific cancer vaccine
WO1997011669A3 (en) MHC-class II restricted melanoma antigens and their use in therapeutic methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/011130

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV2001-3964

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2373256

Country of ref document: CA

Ref country code: CA

Ref document number: 2373256

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 616813

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1020017014170

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 515410

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001/09376

Country of ref document: ZA

Ref document number: 200109376

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 48257/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000930437

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008100381

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020017014170

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000930437

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-3964

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV2001-3964

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000930437

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017014170

Country of ref document: KR